India introduces revised Maximum Retail Prices (MRPs) for a large set of anti-cancer drug formulations, effective Monday, with the aim of reducing what patients pay. Multiple outlets report that the changes cover over 1,000 formulations and come into force as new MRP rules take effect.
The coverage cites the government’s pricing update process and the scale of reported price reductions. Several outlets say the revisions are for 1,364 anti-cancer formulations, with hundreds of brands seeing price cuts of more than 50% and the largest drop approaching about 96%. Some reports also describe how the government is improving price awareness for consumers, including ways to check medicine rates.
Outlets also quantify potential consumer savings. One report gives an annual savings figure of ₹3,540 crore, while another mentions price reductions such as the biggest cut at 96.45%. The number of companies that submitted revised MRPs is also included in at least one account, indicating how widely manufacturers responded to the revision exercise.
